Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer
Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer
复制标题
DOI：
10.1136/jcp.2004.022772
复制
发表时间：
2005-06-01
影响因子：
3.4
通讯作者：
Christiaens, MR
中科院分区：
文献类型：
--
作者：
Huang, HJ;Neven, P;Christiaens, MR
目的：通过免疫组织化学研究原发性可手术乳腺癌的肿瘤特征与 HER-2/neu 之间的关联。方法：对 2000 年至 2003 年 7 月期间在一个中心接受治疗的 1362 名连续原发性乳腺癌患者进行 HER-2/neu 与其他临床病理因素之间的关联评估。使用chi(2)检验进行单变量分析，使用logistic回归进行多变量分析，评估显微镜下肿瘤大小、肿瘤分级、淋巴结状态、患者年龄、雌激素受体(ER)、孕激素受体(PR)和联合ER/PR状态。对激素受体和 HER-2/neu 进行免疫组织化学研究。使用 HER-2/neu DAKO 评分系统，得分 0、1+ 或 2+ 定义为阴性，3+ 定义为阳性。还提供了 DAKO 评分 2+/3+ 与 0/1+ 的数据。 结果：激素受体阴性乳腺癌比激素受体阳性癌症更常见 HER-2/neu 阳性，无论是 ER (28.7% vs 6.8%) 和 PR (19.9% vs 5.9%)。在多变量分析中，ER、PR 和肿瘤分级均与 HER-2/neu 独立相关。在 ER+ 肿瘤中，PR+ 病例中 HER-2/neu 过度表达显着低于 PR- 病例（11.5% vs 5.4%）。 HER-2/ neu 过表达（2.7%）在低肿瘤分级（1-2 级）的 ER+ PR+ 肿瘤大亚组中最低，占所有患者的 46.1%。 结论：ER、PR 和肿瘤分级是原发性可手术乳腺癌女性 HER-2/ neu 过表达的独立预测因子。 ER和PR与HER-2/neu负相关，而肿瘤分级与HER-2/neu正相关。在患有 ER+ 肿瘤的女性中，PR 状态也会影响 HER-2/neu 表达的可能性。
Aims: To investigate the association between tumour characteristics and HER-2/ neu by immunohistochemistry in primary operable breast cancer.Methods: The association between HER-2/ neu and other clinicopathological factors was evaluated in 1362 consecutive patients with primary breast cancer treated between 2000 and July 2003 in one centre. Microscopic tumour size, tumour grade, lymph node status, patient's age, oestrogen receptor ( ER), progesterone receptor ( PR), and joint ER/PR status were evaluated, using the chi(2) test for univariate analysis and logistic regression for multivariate analysis. The hormone receptors and HER-2/ neu were studied immunohistochemically. Using the HER-2/ neu DAKO scoring system, scores of 0, 1+, or 2+ were defined as negative and 3+ as positive. Data for DAKO scores 2+/3+ versus 0/1+ are also presented.Results: Hormone receptor negative breast cancers were more often HER-2/ neu positive than hormone receptor positive cancers, both for ER (28.7% v 6.8%) and PR (19.9% v 5.9%). In multivariate analysis, both ER, PR, and tumour grade were independently associated with HER-2/ neu. In ER+ tumours, HER-2/ neu overexpression was significantly lower in PR+ than in PR- cases (11.5% v 5.4%). HER-2/ neu overexpression (2.7%) was lowest in the large subgroup of ER+ PR+ tumours with low tumour grade ( grade 1 - 2), comprising 46.1% of all patients.Conclusions: ER, PR, and tumour grade are independent predictors for HER-2/ neu overexpression in women with primary operable breast cancer. ER and PR are negatively associated with HER-2/ neu, whereas tumour grade is positively associated with HER-2/ neu. In women with ER+ tumours, PR status also affects the likelihood of HER-2/ neu expression.